Determination of natural radioactivity by gross alpha and beta measurements in ground water samples.

Ş. Turhan,E. Özçıtak,H. Taşkın,A. Varinlioğlu

DOI: https://doi.org/10.1016/j.watres.2013.03.030

IF: 12.8

2013-06-01

Water Research

Abstract:

What problem does this paper attempt to address?

Mechanisms of Congenital Myasthenia Caused by Three Mutations in the COLQ Gene

Xiaona Luo,Chunmei Wang,Longlong Lin,Fang Yuan,Simei Wang,Yilin Wang,Anqi Wang,Chao Wang,Shengnan Wu,Xiaoping Lan,Quanmei Xu,Rongrong Yin,Hongyi Cheng,Yuanfeng Zhang,Jiaming Xi,Jie Zhang,Xiaomin Sun,Jingbin Yan,Fanyi Zeng,Yucai Chen

DOI: https://doi.org/10.3389/fped.2021.679342

IF: 3.569

2021-11-29

Frontiers in Pediatrics

Abstract:The gene encoding collagen like tail subunit of asymmetric acetylcholinesterase (COLQ) is responsible for the transcription of three strands of collagen of acetylcholinesterase, which is attached to the endplate of neuromuscular junctions. Mutations in the COLQ gene are inherited in an autosomal-recessive manner and can lead to type V congenital myasthenia syndrome (CMS), which manifests as decreased muscle strength at birth or shortly after birth, respiratory failure, restricted eye movements, drooping of eyelids, and difficulty swallowing. Here we reported three variants within COLQ in two unrelated children with CMS. An intronic variant (c.393+1G>A) and a novel missense variant (p.Q381P) were identified as compound heterozygous in a 13-month-old boy, with the parents being carriers of each. An intragenic deletion including exons 14 and 15 was found in a homozygous state in a 12-year-old boy. We studied the relative expression of the COLQ and AChE gene in the probands' families, performed three-dimensional protein structural analysis, and analyzed the conservation of the missense mutation c.1142A>C (p.Q381P). The splicing mutation c.393+1G>A was found to affect the normal splicing of COLQ exon 5, resulting in a 27-bp deletion. The missense mutation c.1142A>C (p.Q381P) was located in a conserved position in different species. We found that homozygous deletion of COLQ exons 14–15 resulted in a 241-bp deletion, which decreased the number of amino acids and caused a frameshift translation. COLQ expression was significantly lower in the probands than in the probands' parents and siblings, while AChE expression was significantly higher. Moreover, the mutations were found to cause significant differences in the predicted three-dimensional structure of the protein. The splicing mutation c.393+1G>A, missense mutation c.1A>C (p.Q381P), and COLQ exon 14–15 deletion could cause CMS.

pediatrics
Identification of LAMA2 Compound Heterozygous Variants: a Case Report

Yingchao Ying,Jia Ye,Jue Shen,Guojuan Chen,Kewen Jiang

DOI: https://doi.org/10.21037/tp-24-62

2024-01-01

Translational Pediatrics

Abstract:Background: Laminin-alpha 2 (LAMA2) chain- deficient muscular dystrophy (LAMA2-MD) is the most common congenital muscular dystrophy (CMD) in the world. Its main manifestations are muscle weakness and hypotonia that occur after birth or at early infancy. Case Description: We reported a case of a 3-year-old and 6-month-old boy presented with delayed motor development, elevated creatine kinase (CK) levels, and abnormal white matter in the brain. Whole exome sequencing (WES) showed compound heterozygous variants of the LAMA2 gene. This case reports for the first time the compound heterozygous LAMA2 variants c.5476C>T (p.R1826*) (paternal inheritance) with c.2749 + 2dup (maternal inheritance), as both variants are interpreted as pathogenic/potentially pathogenic variants. Conclusions: This study reports a novel heterozygous variant, including two pathogenic variants in the LAMA2 gene, and highlights the effectiveness of highly efficient exome sequencing applying in patients with undefined CMDs.
COLQ-Congenital myasthenic syndrome in an Iranian cohort: the clinical and genetics spectrum

Omid Hesami,Mahtab Ramezani,Aida Ghasemi,Farzad Fatehi,Ali Asghar Okhovat,Bentolhoda Ziaadini,Ariana Kariminejad,Shahriar Nafissi

DOI: https://doi.org/10.1186/s13023-024-03116-x

2024-03-16

Orphanet Journal of Rare Diseases

Abstract:Congenital myasthenic syndrome (CMS) is a group of neuromuscular disorders caused by abnormal signal transmission at the motor endplate. Mutations in the collagen-like tail subunit gene ( COLQ ) of acetylcholinesterase are responsible for recessive forms of synaptic congenital myasthenic syndromes with end plate acetylcholinesterase deficiency. Clinical presentation includes ptosis, ophthalmoparesis, and progressive weakness with onset at birth or early infancy.

genetics & heredity,medicine, research & experimental
Genetic Spectrum of MCM3AP and Its Relationship with Phenotype of Charcot‐Marie‐Tooth Disease

Hai-Lin Dong,Qiao Wei,Jia-Qi Li,Hong-Fu Li,Ge Bai,Huan Ma,Zhi-Ying Wu

DOI: https://doi.org/10.1111/jns.12377

IF: 5.188

2020-01-01

Journal of the Peripheral Nervous System

Abstract:Mutations in MCM3AP have recently been reported to cause autosomal recessive Charcot-Marie-Tooth disease (CMT). However, only nine CMT families with MCM3AP mutations have been reported and genotype-phenotype correlation remains unclear. This study aimed to investigate the genetic spectrum of MCM3AP and its relationship with phenotype of CMT. Whole-exome sequencing (WES) was performed in the family and variants were validated by Sanger sequencing. Reverse transcription-PCR (RT-PCR) were performed in splicing analysis. We reported a novel splicing variant (c.5634-1G>T) and a known missense variant (c.2633G>A, p.Arg878His). Functional studies showed that c.5634-1G>T led to splicing defect and aberrant transcript eliminated by nonsense-mediated mRNA decay. The symptom of the patient was less severe and slowly progressed with axonal peripheral neuropathy compared to the reported CMT patients. Genotype-phenotype correlation analysis indicated that affected individuals with null mutations presented with delayed independent walking. The percentage of intellectual disability and loss of ambulation in the null group tended to be greater, although this failed to reach statistical significance. Our findings expand the genetic spectrum of MCM3AP and suggest that genotype-phenotype correlation would help genetic counseling of MCM3AP in CMT patients.
A novel mutation leading to elongation of the deduced α1(X) chain results in Metaphyseal Chondrodysplasia type Schmid.

Yimin Zhu,Liping Li,Lijun Zhou,Haibo Mei,Ke Jin,Kun Liu,Wei Xu,Jinsong Tang,Yongjia Yang,Rui Zhao,Xinyu He

DOI: https://doi.org/10.1016/j.cca.2011.03.026

IF: 6.314

2011-01-01

Clinica Chimica Acta

Abstract:Metaphyseal Chondrodysplasia type Schmid (MCDS) is an autosomal dominant skeletal dysplasia, characterized by coxa vara, bowlegs, short limbs and an expanded growth plate hypertrophic zone of the long bone. Previous studies have shown gene mutation of COL10A1 (collagen X, consisting three a1(X) chain) causing human MCDS. To our knowledge, there has been no COL10A1 mutation leading to elongation of the deduced α1(X) chain reported.A four-generation Chinese family with 11 members affected by MCDS was investigated. Mutation screening of the COL10A1 gene was carried out.Besides the typical MCDS features, we found an earlier onset age and a more frequently occurred knee joint pain history in the family. The following sequence analysis disclosed a novel frameshift mutation (c.2029delG) of COL10A1, which leads to the elongation of the deduced α1(X) chain by 5 amino acids and 4 amino acids substitution. This mutation was not found in all unaffected available members and 50 healthy controls.This is a first report of a frameshift mutation leading to elongation of the deduced α1(X) chain associated with MCDS.
A spontaneous missense mutation in the chromodomain helicase DNA-binding protein 8 (CHD8) gene: a novel association with congenital myasthenic syndrome

C Y Lee,M Petkova,S Morales-Gonzalez,N Gimber,J Schmoranzer,A Meisel,W Böhmerle,W Stenzel,M Schuelke,J M Schwarz

DOI: https://doi.org/10.1111/nan.12617

Abstract:Aims: Congenital myasthenic syndromes (CMS) are characterized by muscle weakness, ptosis and episodic apnoea. Mutations affect integral protein components of the neuromuscular junction (NMJ). Here we searched for the genetic basis of CMS in female monozygotic twins. Methods: We employed whole-exome sequencing for mutation detection and Sanger sequencing for segregation analysis. Immunohistology was done with antibodies against CHD8, rapsyn, β-catenin (βCAT) and golgin on fi-bro-blasts, human and mouse muscle. We recorded superresolution images of the NMJ using 3D-structured illumination microscopy. Results: We discovered a spontaneous missense mutation in CHD8 [chr14:g.21,884,051G>A, GRCh37.p11 | c.1732C>T, NM_00117062 | p.(R578C)], the gene encoding chromodomain helicase DNA-binding protein 8. This is the first missense mutation affecting Duplin, the short 110 kDa isoform of CHD8. It is known that CHD8/Duplin negatively regulates βCAT signalling in the WNT pathway and plays a role in chromatin remodelling. Inactivating CHD8 mutations are associated with autism spectrum disorder and intellectual disability in combination with facial dysmorphism, overgrowth and macrocephalus. No muscle-specific phenotype has been reported to date. Co-immunostaining with rapsyn on human and mouse muscle revealed a strong presence of CHD8 at the NMJ being located towards the sarcoplasmic side of the rapsyn cluster, where it co-localizes with βCAT. Conclusion: We hypothesize CHD8 to have a role in the maintenance of the structural integrity and function of the NMJ. Both patients benefited from treatment with 3,4-diaminopyridine, a reversible blocker of voltage-gated potassium channels at the nerve terminal that prolongs the action potential and increases acetylcholine release.
Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes-A Comprehensive Review

Kinji Ohno,Bisei Ohkawara,Xin-Ming Shen,Duygu Selcen,Andrew G Engel

DOI: https://doi.org/10.3390/ijms24043730

2023-02-13

Abstract:Congenital myasthenic syndromes (CMS) are a heterogeneous group of disorders characterized by impaired neuromuscular signal transmission due to germline pathogenic variants in genes expressed at the neuromuscular junction (NMJ). A total of 35 genes have been reported in CMS (AGRN, ALG14, ALG2, CHAT, CHD8, CHRNA1, CHRNB1, CHRND, CHRNE, CHRNG, COL13A1, COLQ, DOK7, DPAGT1, GFPT1, GMPPB, LAMA5, LAMB2, LRP4, MUSK, MYO9A, PLEC, PREPL, PURA, RAPSN, RPH3A, SCN4A, SLC18A3, SLC25A1, SLC5A7, SNAP25, SYT2, TOR1AIP1, UNC13A, VAMP1). The 35 genes can be classified into 14 groups according to the pathomechanical, clinical, and therapeutic features of CMS patients. Measurement of compound muscle action potentials elicited by repetitive nerve stimulation is required to diagnose CMS. Clinical and electrophysiological features are not sufficient to identify a defective molecule, and genetic studies are always required for accurate diagnosis. From a pharmacological point of view, cholinesterase inhibitors are effective in most groups of CMS, but are contraindicated in some groups of CMS. Similarly, ephedrine, salbutamol (albuterol), amifampridine are effective in most but not all groups of CMS. This review extensively covers pathomechanical and clinical features of CMS by citing 442 relevant articles.
Improving Rohn approximation for the real parts of interval matrix eigenvalues

Dorian Florescu,M. Matcovschi,O. Pastravanu

2011-11-28

Abstract:The paper proposes a new approximation method for the upper and lower bounds of the real parts of interval matrix eigenvalues. As a theoretical support, we exploit the properties of the matrix measures corresponding to monotonic (or, equivalently, absolute) vector norms. The numerical approach focuses on the use of the results derived for the matrix measure defined by the Euclidean norm (or 2-norm). The computational procedure is formulated as a minimization problem of a linear objective function constrained by bilinear matrix inequalities. We prove (by mathematical arguments and, separately, by examples) that our estimations are better or, at least, as accurate as those provided by the method due to Rohn (see reference [6]).
An Approach to Solving the Survivable Capacitated Network Design Problem

V. Sridhar,J. Park

DOI: https://doi.org/10.4018/jbdcn.2005040101

2005-04-01

International Journal of Business Data Communications and Networking

Abstract:Survivability refers to keeping a system partially or fully operational when one or more of its components fail. Survivability in telecommunication networks is crucial, as failure of a network component can potentially bring down the whole communication network, as happened in some real-world cases. Adding redundant network components increases the survivability of a network, but cost of the network also increases. In this paper, we consider the design of survivable telecommunications network architecture that uses high-capacity transport facilities. The model considers selection of capacitated links and routing of multicommodity traffic flow in the network that minimizes overall network cost. Two node disjoint paths are selected for each commodity. In case of failure of the primary path, a portion of the traffic for each commodity will be rerouted through the secondary path. The methodology presented in this paper can be used by the network designer to construct cost-effective survivable networks.
COOH-terminal collagen Q (COLQ) mutants causing human deficiency of endplate acetylcholinesterase impair the interaction of ColQ with proteins of the basal lamina

Juan Arredondo,Marian Lara,Fiona Ng,Danielle A. Gochez,Diana C. Lee,Stephanie P. Logia,Joanna Nguyen,Ricardo A. Maselli

DOI: https://doi.org/10.1007/s00439-013-1391-3

2013-11-27

Human Genetics

Abstract:Collagen Q (ColQ) is a key multidomain functional protein of the neuromuscular junction (NMJ), crucial for anchoring acetylcholinesterase (AChE) to the basal lamina (BL) and accumulating AChE at the NMJ. The attachment of AChE to the BL is primarily accomplished by the binding of the ColQ collagen domain to the heparan sulfate proteoglycan perlecan and the COOH-terminus to the muscle-specific receptor tyrosine kinase (MuSK), which in turn plays a fundamental role in the development and maintenance of the NMJ. Yet, the precise mechanism by which ColQ anchors AChE at the NMJ remains unknown. We identified five novel mutations at the COOH-terminus of ColQ in seven patients from five families affected with endplate (EP) AChE deficiency. We found that the mutations do not affect the assembly of ColQ with AChE to form asymmetric forms of AChE or impair the interaction of ColQ with perlecan. By contrast, all mutations impair in varied degree the interaction of ColQ with MuSK as well as basement membrane extract (BME) that have no detectable MuSK. Our data confirm that the interaction of ColQ to perlecan and MuSK is crucial for anchoring AChE to the NMJ. In addition, the identified COOH-terminal mutants not only reduce the interaction of ColQ with MuSK, but also diminish the interaction of ColQ with BME. These findings suggest that the impaired attachment of COOH-terminal mutants causing EP AChE deficiency is in part independent of MuSK, and that the COOH-terminus of ColQ may interact with other proteins at the BL.

genetics & heredity
Characterization of Clinical Phenotypes in Congenital Myasthenic Syndrome Associated with the c.1327delG Frameshift Mutation in CHRNE Encoding the Acetylcholine Receptor Epsilon Subunit

Kristina Kastreva,Teodora Chamova,Stanislava Blagoeva,Stoyan Bichev,Violeta Mihaylova,Stefanie Meyer,Rachel Thompson,Sylvia Cherninkova,Velina Guergueltcheva,Hanns Lochmuller,Ivailo Tournev

DOI: https://doi.org/10.3233/JND-230235

Abstract:Background: Congenital myasthenic syndromes (CMS) are a group of rare but often treatable inherited disorders of neuromuscular transmission characterized by fatigable skeletal muscle weakness. In this paper we present the largest phenotypic analysis to date of a cohort of patients carrying the pathogenic variant c.1327delG in the CHRNE gene, leading to CHRNE-CMS. Objective: This study aims to identify the phenotypic variability in CMS associated with c.1327delG mutation in the CHRNE gene. Methods: Disease specific symptoms were assessed using specific standardized tests for autoimmune myasthenia (Quantitative Myasthenia Gravis score) as well as patient-reported scales for symptom severity. Evaluated clinical manifestations included ocular symptoms (ophthalmoparesis and ptosis), bulbar weakness, axial muscle weakness, proximal and distal muscle weakness, and respiratory function. Patients were allocated into three groups according to clinical impression of disease severity: mild, moderate, and severe. Results: We studied 91 Bulgarian Roma patients, carrying the same causative homozygous CHRNE c.1327delG mutation. Bulbar weakness was present in patients throughout all levels of severity of CHRNE-CMS in this study. However, difficulties in eating and swallowing are more prominent characteristics in the moderate and severe clinical phenotypes. Diplopia and ptosis resulting from fatigue of the extraocular muscles were permanent features regardless of disease severity or age. Levels of axial, proximal and distal muscle weakness were variable between disease groups. The statistical analysis showed significant differences between the patients in the three groups, emphasizing a possible variation in symptom manifestation in the evaluated patient population despite the disease originating from the same genetic mutation. Impairment of respiratory function was more prominent in severely affected patients, which might result from loss of compensatory muscle function in those individuals. Conclusion: Results from our study indicate significant phenotypic heterogeneity leading to mild, moderate, or severe clinical manifestation in CHRNE-CMS, despite the genotypic homogeneity.
Congenital myasthenic syndromes: increasingly complex

Sithara Ramdas,David Beeson,Yin Yao Dong

DOI: https://doi.org/10.1097/wco.0000000000001300

2024-09-04

Current Opinion in Neurology

Abstract:Congenital myasthenia syndromes (CMS) are caused by genetic defects that impair neuromuscular transmission. Efficient synaptic transmission at the neuromuscular junction (NMJ) incorporates many different proteins involved both in the signal transmission itself and in generating the prerequisite specialized synaptic structures. As a consequence, there are multiple pathogenic mechanisms that can underlie CMS. A recent comprehensive review of CMS highlights many of these mechanisms [1▪▪] . There are currently 35 genes reported to be associated with CMS (Fig. 1 and Table 1). The prevalence reported varies considerably between regions, 2.8–14.8 per million (UK), 1.8 per million (Brazil), and 22.2 per million (Slovenia) [2] . Differences are likely to occur because of mutation founder effects in certain regions and historically because of different pick-up rates as new detection technologies are adopted. The clinical use of next-generation sequencing greatly facilitates detection of mutations in larger genes, such as AGRN , LRP4 , MUSK , COLQ , and thus increases in reported prevalence is likely to continue [3–7] . Whilst symptom onset at birth or infancy is the commonest presentation, later onset in childhood and adult life is now increasingly recognized. The clinical phenotypes can vary in the subtypes, but the hallmark is fatigable weakness predominantly affecting axial and proximal limb muscle, ocular, bulbar and or respiratory involvement. A suspected diagnosis is based on typical clinical features, decremental responses of 10% or more on repetitive nerve stimulation (RNS) and/or abnormal jitter and block on single-fibre EMG. It is prudent to note that RNS may show incremental response on high-frequency stimulation in some presynaptic (VAMP1, UNC13A, SYT2, RPH3A) and one synaptic (LAMA5) CMS subtype [8,9] . The inheritance patten in CMS is autosomal recessive except for dominant pattern seen in slow channel syndromes, SNAP25, PURA and some SYT2 patients [1▪▪] . Here, we highlight the widening phenotype spectrum associated with gene mutations that can not only have an effect of the NMJ but also show systemic and brain involvement (Table 2), and on current and emerging therapeutic strategies for CMS.

neurosciences,clinical neurology
Current status of the congenital myasthenic syndromes

Andrew G Engel

DOI: https://doi.org/10.1016/j.nmd.2011.10.009

Abstract:Congenital myasthenic syndromes (CMS) are heterogeneous disorders in which the safety margin of neuromuscular transmission is compromised by one or more specific mechanisms. Clinical, electrophysiologic, and morphologic studies have paved the way for detecting CMS-related mutations in proteins residing in the nerve terminal, the synaptic basal lamina, and in the postsynaptic region of the motor endplate. The disease proteins identified to date include choline acetyltransferase (ChAT), the endplate species of acetylcholinesterase (AChE), β2-laminin, the acetylcholine receptor (AChR), rapsyn, plectin, Na(v)1.4, the muscle specific protein kinase (MuSK), agrin, downstream of tyrosine kinase 7 (Dok-7), and glutamine-fructose-6-phosphate transaminase 1 (GFPT1). Myasthenic syndromes associated with centronuclear myopathies were recently recognized. Analysis of properties of expressed mutant proteins contributed to finding improved therapy for most CMS. Despite these advances, the molecular basis of some phenotypically characterized CMS remains elusive. Moreover, other types of CMS and disease genes likely exist and await discovery.
Novel compound missense variants in MUSK impair LRP4-MUSK-DOK7 complex associated with congenital myasthenic syndrome 9 and insights into genotype-phenotype correlation

Yunliang Qian,Yinmo Jiang,Wenhao Zhou,Bingbing Wu,Huijun Wang

DOI: https://doi.org/10.21203/rs.3.rs-2824737/v1

2023-01-01

Abstract:Abstract Background: Congenital myasthenic syndromes are a group of rare neuromuscular transmission disorders. The muscle-specific kinase gene MUSK is one of the disease-causing genes. Method: Trio whole exome sequencing was performed in a patient family with congenital laryngeal achondroplasia. In vitro experiments in HEK293T cells were performed to evaluate the mutant proteins' subcellular distribution and the interactions with LRP4 and DOK7. Furthermore, we reviewed the genotype-phenotype correlations of MUSK variants from the reported literature and our patient. Result: Two novel missense variants, c.1043A>C(p.Gln348Pro) and c.2360C>T(p.Ala787Val) of MUSK, were detected in an 11-month-old girl. The variants were inherited from maternal and paternal, respectively. Compared with the wild-type MUSK protein, the two variants overexpressed in HEK293T cells localized in cytoplasmic rather than the cell membrane. The Gln348Pro was detected to impair the interaction with LRP4 and DOK7 partly. The Ala787Val variant was detected to impair the interaction with DOK7 completely. The genotype-phenotype analysis demonstrated that patients with biallelic truncation variants had earlier onset age than those with biallelic missense variants or missense variants with truncation variants. While considering biallelic missense variants, we found that the patients with variants localized in the tyrosine kinase domain had earlier onset age than those carrying variants in the Ig-like domain and had a higher mortality rate. Conclusion: In this study, we identified two novel MUSK variants cause severe fatal CMSs, expanding the spectrum of MUSK variants. In addition, our data suggest that the null variants or missense variants localized in tyrosine kinase might lead to more severe outcomes, which could give some reminders in prognostication.
Novel Mutations in the C-terminal Region of GMPPB Causing Limb-Girdle Muscular Dystrophy Overlapping with Congenital Myasthenic Syndrome

Sushan Luo,Shuang Cai,Susan Maxwell,Dongyue Yue,Wenhua Zhu,Kai Qiao,Zhen Zhu,Lei Zhou,Jianying Xi,Jiahong Lu,David Beeson,Chongbo Zhao

DOI: https://doi.org/10.1016/j.nmd.2017.03.004

IF: 3.538

2017-01-01

Neuromuscular Disorders

Abstract:Mutations in the GMPPB gene may underlie both limb girdle muscular dystrophy (LGMD) and congenital myasthenic syndrome (CMS). Forty-one cases have been reported to date and hotspot mutations are emerging in the Caucasian population. Clinical and pathological features of 5 patients with compound heterozygous GMPPB mutations were collected and retrospectively reviewed. In vitro functional analysis was performed to investigate the pathogeneity of GMPPB variants. The patients presented with proximal limb weakness in their first to second decades. Fluctuating muscle weakness, myalgia and calf hypertrophy were the major complaints. Myogenic changes on electromyography and marked attenuation on 3 Hz repetitive nerve stimulation were observed in all patients. Four reported a beneficial response to pyridostigmine. Muscle MRI showed selective involvement in the calf in case 1. Immunolabeling of a-dystroglycan was abnormal for case 1 and case 2. Four novel missense mutations in the C-terminal region of GMPPB were identified, with p.(Arg357His) being present in all the cases. In vitro functional assays demonstrated that these variants did not markedly reduce the amount of GMPPB, but gave rise to an increased propensity for protein aggregation. Increasingly, patients with GMPPB mutations are found to present with an overlapping LGMD/myasthenic syndrome. The mutation spectrum in Chinese patients may differ from that of European populations, with the mutation p.(Arg357His) most frequently found. These mutations may lead to abnormal folding of GMPPB leading to protein aggregates in the cytoplasm rather than an overall loss in protein expression. (C) 2017 Elsevier B.V. All rights reserved.
Protein Kinase A-Dependent Derepression of the Human Prodynorphin Gene via Differential Binding to an Intragenic Silencer Element

Á. M. Carrión,B. Mellström,J. Naranjo

DOI: https://doi.org/10.1128/MCB.18.12.6921

IF: 5.069

1998-12-01

Molecular and Cellular Biology

Abstract:ABSTRACT Induction of the prodynorphin gene has been implicated in medium and long-term adaptation during memory acquisition and pain. By 5′ deletion mapping and site-directed mutagenesis of the human prodynorphin promoter, we demonstrate that both basal transcription and protein kinase A (PKA)-induced transcription in NB69 and SK-N-MC human neuroblastoma cells are regulated by the GAGTCAAGG sequence centered at position +40 in the 5′ untranslated region of the gene (named the DRE, for downstream regulatory element). The DRE repressed basal transcription in an orientation-independent and cell-specific manner when placed downstream from the heterologous thymidine kinase promoter. Southwestern blotting and UV cross-linking experiments with nuclear extracts from human neuroblastoma cells or human brain revealed a protein complex of approximately 110 kDa that specifically bound to the DRE. Forskolin treatment reduced binding to the DRE, and the time course paralleled that for an increase in prodynorphin gene expression. Our results suggest that under basal conditions, expression of the prodynorphin gene is repressed by occupancy of the DRE site. Upon PKA stimulation, binding to the DRE is reduced and transcription increases. We propose a model for human prodynorphin activation through PKA-dependent derepression at the DRE site.
STREPTOMYCIN TREATMENT OF TUBERCULOUS TRACHEO-BRONCHITIS.

E. Bogen,L. A. Brewer

1948-04-01

Abstract:Progressive heart disease during and following penicillin therapy was evidenced by increasing cardiac size (Figure 1). As late as May 17, 1945, fluoroscopic examination and films of the heart showed no evidence of cardiac enlargement. On May 13, 1946, less than a year later, the transverse diameter of the heart had increased from 11.3 cm. to 17.8 cm. The cardiothoracic ratio increased from 0.38 to 0.59. The longitudinal diameter of the heart increased from 15 cm. to 20.5 cm. In the right oblique position x-rays indicate the development of a marked posterior deviation of the esophagus which indicates left auricular enlargement. Electrocardiograms taken before and after treatment show a change from a normal electrocardiogram to one in which there are large notched P waves, right axis deviation, and inverted T waves in leads II and III. There was a definite change in the character of the heart findings. On the original examination the systolic murmur at the apex was a blowing murmur intensity grade II, and the blood pressure was 150/80. On re-examination on May 10, 1946, the intensity of the systolic murmur at the apex was graded as IV to V. It extended throughout the whole systole and ended with an unusually loud second sound which is unusual at the apex. No diastolic murmurs were heard. The blood pressure on May 10 was 148/106, and the diastolic pressure was consistently over 100 while the systolic pressure rose as high as 168. Signs of congestive heart failure were thought to be present at the time of the patient's visit to the outpatient clinic in April, 1946, and he was admitted to the General Hospital for a period of ten days. At this time digitalis and ammonium chloride were given. Following this the shortness of breath and swelling of the ankles markedly improved, and the patient continued on the same program. He has returned to work.
Diagnostic yield of a practical electrodiagnostic protocol discriminating between different congenital myasthenic syndromes

Tanya Stojkovic,Marion Masingue,Helène Turmel,Marianne Hezode-Arzel,Anthony Béhin,Sarah Leonard-Louis,Guillaume Bassez,Stéphanie Bauché,Patricia Blondy,Pascale Richard,Damien Sternberg,Bruno Eymard,Emmanuel Fournier,Rocío Nur Villar-Quiles

DOI: https://doi.org/10.1016/j.nmd.2022.10.001

Abstract:Congenital myasthenic syndromes (CMS) are a group of heterogeneous diseases of the neuromuscular junction. We report electrodiagnostic testing (EDX) and genetic findings in a series of 120 CMS patients tested with a simple non-invasive EDX workup with surface recording of CMAPs and 3Hz repetitive nerve stimulation of accessory, radial and deep fibular nerves. Five ENMG phenotypes were retrieved based on the presence or not of R-CMAPs and the distribution pattern of decremental CMAP responses which significantly correlated with genetic findings (p <0.00001). R-CMAPs were found in all COLQ-mutated patients (CMS1A) and Slow Channel CMS (SCCMS) (CMS1B). CMS1A exhibited greater decrements in accessory nerve RNS than CMS1B. Patients without R-CMAPs were classified into CMS2A (DOK7-, MUSK-, GFPT1-, GMPPB-, TOR1AIP-mutated) when exhibiting predominant accessory nerve RNS decrements, CMS2B (CHRNE, CHRND, RAPSN) with predominant radial nerve RNS decrements, or CMS2C (AGRN) if there were predominant fibular decrements. Our algorithm may have a major impact on diagnostic and therapeutic monitoring in CMS patients, as well as for validation of the pathogenicity of genetic variants. It should also be part of the evaluation of unexplained muscle weakness or complex neuromuscular phenotypes.
Congenital myasthenia syndrome in a Chinese family with mutations in MUSK: A hotspot mutation and literature review.

Yiqi Liu,Kai Qiao,Chong Yan,Jie Song,Xiao Huan,Sushan Luo,Jiahong Lu,Chongbo Zhao,Jianying Xi

DOI: https://doi.org/10.1016/j.jocn.2020.03.036

IF: 2.116

2020-01-01

Journal of Clinical Neuroscience

Abstract:•Two cases of late onset CMS with a homozygous hotspot mutation, c.308A > G in MUSK were presented.•Patients with nonsense, frameshift and splicing mutations showed a more severe phenotype.•The clinical features of patients with a homozygous c.308A > G mutation were proposed.
Clinical features of the myasthenic syndrome arising from mutations in GMPPB

Pedro M Rodríguez Cruz,Katsiaryna Belaya,Keivan Basiri,Maryam Sedghi,Maria Elena Farrugia,Janice L Holton,Wei Wei Liu,Susan Maxwell,Richard Petty,Timothy J Walls,Robin Kennett,Matthew Pitt,Anna Sarkozy,Matt Parton,Hanns Lochmüller,Francesco Muntoni,Jacqueline Palace,David Beeson

DOI: https://doi.org/10.1136/jnnp-2016-313163

Abstract:Background: Congenital myasthenic syndrome (CMS) due to mutations in GMPPB has recently been reported confirming the importance of glycosylation for the integrity of neuromuscular transmission. Methods: Review of case notes of patients with mutations in GMPPB to identify the associated clinical, neurophysiological, pathological and laboratory features. In addition, serum creatine kinase (CK) levels within the Oxford CMS cohort were retrospectively analysed to assess its usefulness in the differential diagnosis of this new entity. Results: All patients had prominent limb-girdle weakness with minimal or absent craniobulbar manifestations. Presentation was delayed beyond infancy with proximal muscle weakness and most patients recall poor performance in sports during childhood. Neurophysiology showed abnormal neuromuscular transmission only in the affected muscles and myopathic changes. Muscle biopsy showed dystrophic features and reduced α-dystroglycan glycosylation. In addition, myopathic changes were present on muscle MRI. CK was significantly increased in serum compared to other CMS subtypes. Patients were responsive to pyridostigimine alone or combined with 3,4-diaminopyridine and/or salbutamol. Conclusions: Patients with GMPPB-CMS have phenotypic features aligned with CMS subtypes harbouring mutations within the early stages of the glycosylation pathway. Additional features shared with the dystroglycanopathies include myopathic features, raised CK levels and variable mild cognitive delay. This syndrome underlines that CMS can occur in the absence of classic myasthenic manifestations such as ptosis and ophthalmoplegia or facial weakness, and links myasthenic disorders with dystroglycanopathies. This report should facilitate the recognition of this disorder, which is likely to be underdiagnosed and can benefit from symptomatic treatment.

Determination of natural radioactivity by gross alpha and beta measurements in ground water samples.

Mechanisms of Congenital Myasthenia Caused by Three Mutations in the COLQ Gene

Identification of LAMA2 Compound Heterozygous Variants: a Case Report

COLQ-Congenital myasthenic syndrome in an Iranian cohort: the clinical and genetics spectrum

Genetic Spectrum of MCM3AP and Its Relationship with Phenotype of Charcot‐Marie‐Tooth Disease

A novel mutation leading to elongation of the deduced α1(X) chain results in Metaphyseal Chondrodysplasia type Schmid.

A spontaneous missense mutation in the chromodomain helicase DNA-binding protein 8 (CHD8) gene: a novel association with congenital myasthenic syndrome

Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes-A Comprehensive Review

Improving Rohn approximation for the real parts of interval matrix eigenvalues

An Approach to Solving the Survivable Capacitated Network Design Problem

COOH-terminal collagen Q (COLQ) mutants causing human deficiency of endplate acetylcholinesterase impair the interaction of ColQ with proteins of the basal lamina

Characterization of Clinical Phenotypes in Congenital Myasthenic Syndrome Associated with the c.1327delG Frameshift Mutation in CHRNE Encoding the Acetylcholine Receptor Epsilon Subunit

Congenital myasthenic syndromes: increasingly complex

Current status of the congenital myasthenic syndromes

Novel compound missense variants in MUSK impair LRP4-MUSK-DOK7 complex associated with congenital myasthenic syndrome 9 and insights into genotype-phenotype correlation

Novel Mutations in the C-terminal Region of GMPPB Causing Limb-Girdle Muscular Dystrophy Overlapping with Congenital Myasthenic Syndrome

Protein Kinase A-Dependent Derepression of the Human Prodynorphin Gene via Differential Binding to an Intragenic Silencer Element

STREPTOMYCIN TREATMENT OF TUBERCULOUS TRACHEO-BRONCHITIS.

Diagnostic yield of a practical electrodiagnostic protocol discriminating between different congenital myasthenic syndromes

Congenital myasthenia syndrome in a Chinese family with mutations in MUSK: A hotspot mutation and literature review.

Clinical features of the myasthenic syndrome arising from mutations in GMPPB